Business Description
Stoke Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US86150R1077
Description
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 123.84 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.22 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -17.9 | |||||
| 3-Year EPS without NRI Growth Rate | -15.1 | |||||
| 3-Year FCF Growth Rate | -13.3 | |||||
| 3-Year Book Growth Rate | -23.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 44 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.14 | |||||
| 9-Day RSI | 59.18 | |||||
| 14-Day RSI | 53.21 | |||||
| 6-1 Month Momentum % | -2.78 | |||||
| 12-1 Month Momentum % | 176.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.67 | |||||
| Quick Ratio | 6.67 | |||||
| Cash Ratio | 6.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | -17.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -755.65 | |||||
| Net Margin % | -683.31 | |||||
| FCF Margin % | -531.27 | |||||
| ROE % | -57.17 | |||||
| ROA % | -41.83 | |||||
| ROIC % | -337.71 | |||||
| 3-Year ROIIC % | -226.95 | |||||
| ROC (Joel Greenblatt) % | -1071.21 | |||||
| ROCE % | -53.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 41.59 | |||||
| PB Ratio | 2.82 | |||||
| Price-to-Tangible-Book | 2.82 | |||||
| EV-to-EBIT | -3.58 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | -3.66 | |||||
| EV-to-Forward-EBITDA | -2.97 | |||||
| EV-to-Revenue | 27.05 | |||||
| EV-to-Forward-Revenue | 11.14 | |||||
| EV-to-FCF | -5.09 | |||||
| Price-to-Net-Current-Asset-Value | 2.96 | |||||
| Price-to-Net-Cash | 3.16 | |||||
| Earnings Yield (Greenblatt) % | -27.93 | |||||
| FCF Yield % | -11.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Stoke Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 14.036 | ||
| EPS (TTM) (€) | -2.016 | ||
| Beta | 1.12 | ||
| Volatility % | 107.69 | ||
| 14-Day RSI | 53.21 | ||
| 14-Day ATR (€) | 0.268768 | ||
| 20-Day SMA (€) | 11.115 | ||
| 12-1 Month Momentum % | 176.32 | ||
| 52-Week Range (€) | 3.4 - 16.1 | ||
| Shares Outstanding (Mil) | 52.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Stoke Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Stoke Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Stoke Therapeutics Inc Frequently Asked Questions
What is Stoke Therapeutics Inc(FRA:0GT)'s stock price today?
The current price of FRA:0GT is €11.60. The 52 week high of FRA:0GT is €16.10 and 52 week low is €3.40.
When is next earnings date of Stoke Therapeutics Inc(FRA:0GT)?
The next earnings date of Stoke Therapeutics Inc(FRA:0GT) is 2024-11-07 Est..
Does Stoke Therapeutics Inc(FRA:0GT) pay dividends? If so, how much?
Stoke Therapeutics Inc(FRA:0GT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers